Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biotalys
  6. Summary
    BTLS   BE0974386188

BIOTALYS

(BTLS)
  Report
Real-time Euronext Bruxelles  -  03:42:36 2023-01-27 am EST
6.980 EUR   -0.29%
01/26Biotalys Targets 2026 Release of Biofungicide After Hitting Production Efficiency Milestone
MT
01/26Biotalys Achieves Significant Progress in Manufacturing Capabilities for Evoca
GL
01/26Biotalys Achieves Significant Progress in Manufacturing Capabilities for Evoca
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
6.96(c) 6.92(c) 6.92(c) 7(c) 6.98 Last
2 463 911 164 21 810 6 943 Volume
-0.29% -0.57% 0.00% +1.16% -0.29% Change
More quotes
Estimated financial data (e)
Sales 2022 2,00 M 2,17 M 2,17 M
Net income 2022 -22,0 M -23,9 M -23,9 M
Net cash position 2022 24,0 M 26,0 M 26,0 M
P/E ratio 2022 -10,0x
Yield 2022 -
Sales 2023 3,00 M 3,26 M 3,26 M
Net income 2023 -30,0 M -32,6 M -32,6 M
Net Debt 2023 7,00 M 7,60 M 7,60 M
P/E ratio 2023 -7,29x
Yield 2023 -
Capitalization 217 M 235 M 235 M
EV / Sales 2022 96,3x
EV / Sales 2023 74,5x
Nbr of Employees 75
Free-Float 53,0%
More Financials
Company
Biotalys specializes in the development of products for crop and food protection. The company offers advanced protein-based biocontrols that effectively and selectively target pests and pathogens, while maintaining the protection of the environment. 
Sector
Fishing & Farming
Calendar
03/24Earnings Release
More about the company
Ratings of Biotalys
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOTALYS
01/26Biotalys Targets 2026 Release of Biofungicide After Hitting Production Efficiency Miles..
MT
01/26Biotalys Achieves Significant Progress in Manufacturing Capabilities for Evoca
GL
01/26Biotalys Achieves Significant Progress in Manufacturing Capabilities for Evoca
AQ
2022Results of the Extraordinary Shareholders' Meeting
GL
2022Results of the Extraordinary Shareholders' Meeting
AQ
2022Biotalys Creates Scientific Advisory Committee with Leading Experts
GL
2022Biotalys Creates Scientific Advisory Committee with Leading Experts
AQ
2022Biotalys Announces Establishment of a Scientific Advisory Committee
CI
2022Invitation to an Extraordinary Shareholders' Meeting
GL
2022Invitation to an Extraordinary Shareholders' Meeting
AQ
2022Biotalys announces participation at investor and industry events for the remainder of 2..
GL
2022Biotalys announces participation at investor and industry events for the remainder of 2..
AQ
2022Biotalys and Novozymes announce successful Evoca™ feasibility study
GL
2022Biotalys and Novozymes announce successful Evoca™ feasibility study
AQ
2022Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study
CI
More news
News in other languages on BIOTALYS
01/26Bel20 vermoedelijk hoger van start na laat herstel op Wall Street
01/26Progressie bij productie Evoca van Biotalys
01/12Bel20 fractioneel hoger geopend
2022Bel20 levert ruim half procent in
2022Rode opening Brussel
More news
Chart BIOTALYS
Duration : Period :
Biotalys Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOTALYS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 7,00 €
Average target price 9,00 €
Spread / Average Target 28,6%
EPS Revisions
Managers and Directors
Patrice SellŔs Chief Executive Officer & Director
Wim Ottevaere Chief Financial Officer
Simon E. Moroney Chairman
Marnix Peferoen Chief Technology Officer
Carlo Boutton Chief Scientific Officer
Sector and Competitors